FDA Approval for Cobenfy Schizophrenia Drug

This is a U.S. news story, published by CNBC, that relates primarily to Cobenfy news.

U.S. news

For more U.S. news, you can click here:

more U.S. news

Cobenfy news

For more Cobenfy news, you can click here:

more Cobenfy news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

CNBC news

For more news from CNBC, you can click here:

more news from CNBC

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

schizophrenia drug Cobenfy

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest anticipated schizophrenia drug news, Bristol Myers Squibb executives news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

Bristol Myers Squibb

CNBC

•

FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in decades

Summary

Nutrition label

84% Informative

Cobenfy will cost $ 1,850 for a month 's supply or $ 22,500 annually before insurance and other rebates.

The drug is a badly needed new option for the nearly 3 million adults in the U.S. living with schizophrenia.

Schizophrenia affects how a person thinks, feels and behaves, and can cause paranoia, delusions, hallucinations, and changes in emotions, movements.

Cobenfy met the main goal of three clinical trials, significantly decreasing symptoms of schizophrenia compared with a placebo.

The approval was based on data from three trials comparing Cobenf to a placebo, as well as two longer-term studies that examined how safe and tolerable the drug is for up to one year .

The company also plans to study the drug's potential to treat bipolar mania and irritability associated with autism.

VR Score

Informative language

Neutral language

Article tone

semi-formal

Language

English

Language complexity

Offensive language

possibly offensive

Hate speech